Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05812755 · ClinicalTrials.gov registry record · Phase 4
SGC Stimulation, Perioperative Vascular Reactivity, and Organ Injury in Cardiac Surgery
A Phase 4 study of Endothelial Dysfunction and Vascular Diseases, sponsored by Vanderbilt University Medical Center.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 170
- Enrollment target
- 1
- Study location
NCT05812755 is a Phase 4 study of Endothelial Dysfunction and Vascular Diseases that is actively recruiting participants, run by Vanderbilt University Medical Center. The registered enrollment target is 170 participants, above the 88-participant average among 45 other Endothelial Dysfunction trials with a reported enrollment target (93% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05812755, a Phase 4 study of Endothelial Dysfunction and Vascular Diseases, is actively recruiting participants, sponsored by Vanderbilt University Medical Center.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 170 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this mechanistic clinical trial is to learn about the effects of medications called soluble guanylyl cyclase stimulators on vascular function and markers of kidney and brain injury in patients having heart surgery. The main questions it aims to answer are: 1. Does soluble guanylyl cyclase stimulation improve blood vessel function compared to placebo? 2. Does soluble guanylyl cyclase stimulation decrease markers of kidney injury and brain injury compared to placebo? Participants will be randomized to a soluble guanylyl cyclase stimulator called vericiguat or placebo, and researchers will compare vascular function and markers of brain and kidney injury to see if vericiguat improves vascular function and reduces markers of injury. This will provide important information to determine the underlying reasons that patients have some kidney and brain function problems after having heart surgery.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Vericiguat
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2023-05-19 |
| Est. Completion | 2027-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05812755
The ClinicalTrials.gov registry entry for NCT05812755 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 88-participant average among 45 other Endothelial Dysfunction trials with a reported enrollment target (93% higher). The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Endothelial Dysfunction appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05812755 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT05812755 about?
NCT05812755 is a clinical study titled "SGC Stimulation, Perioperative Vascular Reactivity, and Organ Injury in Cardiac Surgery". The goal of this mechanistic clinical trial is to learn about the effects of medications called soluble guanylyl cyclase stimulators on vascular function and markers of kidney and brain injury in patients having heart surgery. The main questions it aims to answer are: 1. Does soluble guanylyl cycla...
What is the current status of trial NCT05812755?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 170 participants. The study started on 2023-05-19. Estimated completion is 2027-11.
What conditions does trial NCT05812755 study?
This clinical trial studies the following conditions: Endothelial Dysfunction, Vascular Diseases, Kidney Injury, Brain Disease, Vascular Inflammation.
What interventions are being tested in trial NCT05812755?
The interventions under investigation include: Placebo (DRUG), Vericiguat (DRUG).
Who is sponsoring clinical trial NCT05812755?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05812755 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endothelial Dysfunction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
-
Effect of a Daily Supplement on Plasma PAI-1 Levels
RECRUITING · Phase 1
-
Role of Endothelial Function in SCI CVD Risk
RECRUITING
-
The Iowa ACEs and Sleep Cohort and Manipulating Sleep in Young Adults With ACEs Studies
RECRUITING · NA
-
Role of ET-1, Physical Activity, and Sedentary Behavior in Microvascular Dysfunction Following GDM
RECRUITING · Early Phase 1
-
B-Complex: A Nutraceutical SANS Countermeasure
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.